Publishers are flooding billboards, subways, and screens with ads for themselves-many for the first time in history.

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...